Adirondack Trust Company’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.51K Hold
100
﹤0.01% 536
2026
Q1
$1.09K Hold
100
﹤0.01% 523
2025
Q4
$1.29K Hold
100
﹤0.01% 515
2025
Q3
$1.29K Hold
100
﹤0.01% 492
2025
Q2
$1.78K Hold
100
﹤0.01% 459
2025
Q1
$1.78K Hold
100
﹤0.01% 455
2024
Q4
$2.98K Hold
100
﹤0.01% 439
2024
Q3
$1.56K Hold
100
﹤0.01% 471
2024
Q2
$1.71K Hold
100
﹤0.01% 466
2024
Q1
$1.56K Hold
100
﹤0.01% 480
2023
Q4
$1.53K Hold
100
﹤0.01% 475
2023
Q3
$1.61K Hold
100
﹤0.01% 459
2023
Q2
$3.26K Hold
100
﹤0.01% 417
2023
Q1
$6.01K Hold
100
﹤0.01% 384
2022
Q4
$7.33K Hold
100
﹤0.01% 360
2022
Q3
$8K Hold
100
﹤0.01% 349
2022
Q2
$7K Hold
100
﹤0.01% 355
2022
Q1
$8K Hold
100
﹤0.01% 346
2021
Q4
$8K Hold
100
﹤0.01% 316
2021
Q3
$10K Hold
100
﹤0.01% 317
2021
Q2
$22K Hold
100
0.01% 243
2021
Q1
$13K Hold
100
0.01% 275
2020
Q4
$16K Hold
100
0.01% 252
2020
Q3
$11K Hold
100
0.01% 241
2020
Q2
$8K Hold
100
0.01% 263
2020
Q1
$7K Hold
100
0.01% 254
2019
Q4
$8K Hold
100
0.01% 265
2019
Q3
$7K Buy
+100
New +$8K ﹤0.01% 274

Other funds holding NVCR

Adirondack Trust Company's NVCR Position: Q2 2026 in Review

Adirondack Trust Company held its NovoCure (NVCR) position steady in Q2 2026 at 100 shares worth $1.51K. The position accounts for ﹤0.01% of the portfolio, ranked #536.

Adirondack Trust Company first reported a position in NVCR in Q3 2019 and has held it in 28 quarters since. The position peaked at $22K in Q2 2021. 15 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Adirondack Trust Company held 100 shares of NovoCure worth $1.51K as of Q2 2026.
  • Adirondack Trust Company left its NovoCure share count unchanged in Q2 2026.
  • NovoCure made up ﹤0.01% of Adirondack Trust Company's portfolio in Q2 2026, its #536 holding.
  • Adirondack Trust Company first reported a position in NovoCure in Q3 2019 and has held it in 28 quarters since.
  • Adirondack Trust Company's NovoCure position peaked at $22K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Adirondack Trust Company's 13F filing for Q2 2026, filed 16 Jul 2026.